

Special Issue

Novel Drug Compositions for Ischemic Stroke: Mechanisms and Clinical Applications

Message from the Guest Editors

Ischemic stroke is one of the leading causes of disability and mortality, with limited treatment options available for effective recovery. Recent research has focused on developing novel drugs and innovative procedures to address the complexities of ischemic brain injury, aiming to improve patient outcomes. Key mechanisms under investigation include the modulation of excitotoxicity, oxidative stress, inflammation, and apoptosis, which play pivotal roles in neuronal damage. This Special Issue provides a unique platform to cover the mechanisms underlying ischemic stroke and the development of new therapeutic agents designed to intervene at critical stages of the ischemic cascade. By bringing together cutting-edge research on novel drug compositions, we aim at highlighting their potential in transforming ischemic stroke treatment. Investigating both molecular mechanisms and clinical implications, this collection will pave the way for future breakthroughs in stroke therapy and improved patient care. We look forward to your valuable contributions to advancing stroke therapeutics!

Guest Editors

Prof. Dr. Jasenka Mrsic-Pelcic

Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia

Dr. Anja Harej Hrkać

Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia

Deadline for manuscript submissions

25 September 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/233838

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)